Terms: = Endocrine gland cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Treatment
203 results:
1. Radiation-Activated Cobalamin-Kinase Inhibitors for treatment of Pancreatic Ductal Adenocarcinoma.
Gendron LN; Sheveland CG; Gunn JR; Pogue BW; Shell TA; Shell JR
Mol Pharm; 2024 Jan; 21(1):137-142. PubMed ID: 37989273
[TBL] [Abstract] [Full Text] [Related]
2. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
3. src is a target molecule of mannose against pancreatic cancer cells growth in vitro & in vivo.
Xie J; Wu S; Liao W; Ning J; Ding K
Glycobiology; 2023 Oct; 33(10):766-783. PubMed ID: 37658770
[TBL] [Abstract] [Full Text] [Related]
4. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.
Gutic B; Bozanovic T; Mandic A; Dugalic S; Todorovic J; Dugalic MG; Sengul D; Detanac DA; Sengul I; Detanac D; Kesicioglu T; Soares Junior JM
Clinics (Sao Paulo); 2023; 78():100204. PubMed ID: 37148829
[TBL] [Abstract] [Full Text] [Related]
5. treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract] [Full Text] [Related]
6. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
Jiang Y; Song L; Lin Y; Nowialis P; Gao Q; Li T; Li B; Mao X; Song Q; Xing C; Zheng G; Huang S; Jin L
Oncogene; 2023 May; 42(20):1672-1684. PubMed ID: 37020040
[TBL] [Abstract] [Full Text] [Related]
7. Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach.
Agrawal S; Das R; Singh AK; Kumar P; Shukla PK; Bhattacharya I; Tripathi AK; Mishra SK; Tiwari KN
Med Oncol; 2023 Apr; 40(5):133. PubMed ID: 37010624
[TBL] [Abstract] [Full Text] [Related]
8. Targeting src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models.
Su L; Chen Y; Huang C; Wu S; Wang X; Zhao X; Xu Q; Sun R; Kong X; Jiang X; Qiu X; Huang X; Wang M; Wong PP
Sci Transl Med; 2023 Jan; 15(678):eabl7895. PubMed ID: 36630483
[TBL] [Abstract] [Full Text] [Related]
9. src-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway.
Wang Y; Luo X; Wu N; Liao Q; Wang J
Med Oncol; 2023 Jan; 40(2):76. PubMed ID: 36625999
[TBL] [Abstract] [Full Text] [Related]
10. Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1
Wang Q; Pan Y; Luo H; Zhang Y; Gao F; Wang J; Zheng J
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500678
[TBL] [Abstract] [Full Text] [Related]
11. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic cancer.
Chen H; Zhou W; Bian A; Zhang Q; Miao Y; Yin X; Ye J; Xu S; Ti C; Sun Z; Zheng J; Chen Y; Liu M; Yi Z
Clin Cancer Res; 2023 Feb; 29(4):815-830. PubMed ID: 36374556
[TBL] [Abstract] [Full Text] [Related]
12. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
13. Small molecule inhibitor against onco-mucins disrupts src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
Zhang C; Atri P; Nallasamy P; Parte S; Rauth S; Nimmakayala RK; Marimuthu S; Chirravuri-Venkata R; Bhatia R; Halder S; Shah A; Cox JL; Smith L; Kumar S; Foster JM; Kukreja RC; Seshacharyulu P; Ponnusamy MP; Batra SK
Cancer Lett; 2022 Dec; 551():215922. PubMed ID: 36285687
[TBL] [Abstract] [Full Text] [Related]
14. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
[TBL] [Abstract] [Full Text] [Related]
15. Opposite Effects of src Family Kinases on YAP and ERK Activation in Pancreatic cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract] [Full Text] [Related]
16. A Rare Case of Synchronous Intraductal Papillary Mucinous Neoplasm-Associated Pancreatic Adenocarcinoma and Signet Ring Cell Gastric Adenocarcinoma.
Shupp B; Liaquat H; Rollins S; Stoll L; Singh G; Quiros RM; Matin A
Am J Case Rep; 2022 Aug; 23():e935242. PubMed ID: 35939415
[TBL] [Abstract] [Full Text] [Related]
17. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract] [Full Text] [Related]
18. Potential therapeutic effects of hAMSCs secretome on Panc1 pancreatic cancer cells through downregulation of SgK269, E-cadherin, vimentin, and snail expression.
Alidoust Saharkhiz Lahiji M; Safari F
Biologicals; 2022 Apr; 76():24-30. PubMed ID: 35216916
[TBL] [Abstract] [Full Text] [Related]
19. The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 signaling.
Safari F; Shafiee Nejad N; Aghaei Nejad A
Med Oncol; 2022 Jan; 39(3):28. PubMed ID: 35059869
[TBL] [Abstract] [Full Text] [Related]
20. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
[TBL] [Abstract] [Full Text] [Related]
[Next]
